Ranbaxy Laboratories (Delisted) share news and announcements
BSE: 500359
Last traded ₹859.80 on 1 Apr 2015
Delisted on 30 Mar 2016.
Ranbaxy Laboratories share news and announcements
790 announcements, routine notices left out, newest first. Page 3 of 16.
Jul 2014
29 Jul · Limited Review for June 30, 2014
14 Jul · Allotment of Equity Shares
ESOPs Allotment Committee of Directors at its meeting held on July 14, 2014 has allotted 207,529 Equity Shares on exercise of stock options ....9 Jul · Shareholding Pattern For June 30, 2014
Jun 2014
17 Jun · Meeting
With reference to the earlier letter dated June 10, 2014 regarding the ensuing Annual General Meeting of the Company to be held on July 28, 2014 (AGM). Ranbaxy Laboratories Ltd has ....13 Jun · Board meeting
Inter-alia to consider and approve Standalone and Consolidated Unaudited Financial Results for the first quarter ending June 30, 2014 as reviewed by the Statutory Auditors of the Company. Further, Company has inform the Exchange that the Trading window will remain closed from July 16, 2014 to July 30, 2014 (both days inclusive) in terms of the provisions of the Company's Code for Prevention for Insider Trading,13 Jun · Results
Meeting of the Board of Directors of the Company has been convened to be held on July 29, 2014, inter-alia, to consider and approve Standalone ....10 Jun · Meeting
Company has fixed Book Closure from July 19, 2014 to July 28, 2014 for the purpose of Annual general Meeting of the Company to be held on July 28, 2014.10 Jun · Meeting
Register of Members & Share Transfer Books of the Company will remain closed from July 19, 2014 to July 28, 2014 (both days inclusive) ....
May 2014
28 May · Legal
Exchange had sought clarification from Ranbaxy Laboratories Ltd with respect to the news articles appeared on May 24, 2014 regarding Andhra Pradesh High Court vacating the stay on the ....9 May · Results
Standalone Results for the period ended on 31-MAR-2014 as follows: Net Sales of Rs. 665703.9 lacs for period ending on 31-MAR-2014. Net Profit / (Loss) of Rs. (87899.5) lacs for the period ending on 31-MAR-2014.9 May · Results
Standalone Results for the quarter ended on 31-MAR-2014 as follows: Net Sales of Rs. 122458.6 lacs for the quarter ending on 31-MAR-2014 . Net Profit / (Loss) of Rs. 89785.9 lacs for the quarter ending on 31-MAR-2014.9 May · Results
Consolidated Results for the period ended on 31-MAR-2014 as follows: Net Sales of Rs. 1304032.4 lacs for period ending on 31-MAR-2014. Net Profit / (Loss) of Rs. (108525.2) lacs for the period ending on 31-MAR-2014.9 May · Results
Consolidated Results for the quarter ended on 31-MAR-2014 as follows: Net Sales of Rs. 243613.2 lacs for the quarter ending on 31-MAR-2014 . Net Profit / (Loss) of Rs. (7365.4) lacs for the quarter ending on 31-MAR-2014.2 May · Clarifies on News item
With reference to the news item appearing in the Media titled "Sun-Ranbaxy merger runs into legal wrangle", Ranbaxy Laboratories Ltd has Clarified to BSE as under: "The Company has ....
Apr 2014
14 Apr · Allotment of Equity Shares
ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on April 14, 2014, allotted 26,747 Equity Shares on exercise ....11 Apr · Board meeting
Meeting of the Board of Directors of the Company will be held on May 09, 2014, inter alia, to consider and approve Audited Financial Results ....7 Apr · Analysts
7 Apr · Sun Pharma to acquire Ranbaxy in a US$ 4 billion landmark transaction
7 Apr · Updates
United States Attorney's Office for the District of New Jersey has issued an administrative subpoena dated March 13, 2014 to Ranbaxy seeking ....5 Apr · Shareholding Pattern for March 31, 2014
Mar 2014
18 Mar · Rating
Credit Analysis & Research Limited (CARE), has revised credit rating for long term debt instruments issued by the Company, from CARE AA+ (DoubIe A Plus) to CARE AA (Double A). Long term Instruments with CARE AA rating are considered to have high degree of safety regarding timely payment of financial obligations and carry very low credit risk.However, CARE has reaffirmed the CARE A1+(A One Plus) rating assigned to the short term bank facilities of the Company. Short Term Debt Instruments with CARE rating of A1+ are considered to have very strong degree of safety regarding timely payment of financial obligations and carry lowest credit risk.